Policy & Regulation
Paraxel Collaborates with Eli Lilly to Develop China's Clinical Research Workforce
7 December 2018 - - US-based biopharmaceutical services provider Paraxel has forged a new collaboration with US-based biopharmaceutical company Eli Lilly and Company (NYSE: LLY) to launch a clinical research learning and development program in China, the company said.

The programme will bring high-value training opportunities to China's clinical trial sites and investigators, enhancing the execution of local clinical trials and driving innovation in China's biopharmaceutical industry.

To encourage innovation in drug development, the Chinese government recently released a series of new policies for clinical research, resulting in a sharp increase in the number of clinical trials in China.

According to China's clinical trial registration platform, 1,258 drug clinical trials were registered and publicised for the first time in China in 2017, an increase of 62.66% compared to 2016.

This increase in clinical research demands has put a strain on the clinical research capacity and resources in China.

A recent report indicates that the total number of class 1.1 chemical drugs and class 1 biologic drugs approved for clinical trials from January to October 2017 was three times that of 2014.

Still, the number of GCP-qualified clinical trial sites did not significantly increase between 2014 and 2016.

Paraxel and Lilly's collaboration is based on a shared vision to address this unmet need and promote globalization and innovation of the market's drug development.

The joint programme will use curriculum developed by Paraxel Academy for clinical trial investigators, and issue certifications to professionals who complete the training.

Designed by clinical research practitioners, the curriculum combines the latest policies, regulations and clinical research technologies.

It also uses behaviour-oriented curriculum design, real-world cases, as well as advanced knowledge and industry trends, to provide world-class expertise and practical experience for clinical research investigators.

The curriculum has been reviewed and certified by TransCelerate BioPharma, Inc., an international non-profit organisation focused on biopharmaceutical research and development.

A recent research report conducted by the Economist Intelligence Unit and commissioned by Paraxel identified workforce readiness as a key enabler of innovation in the life sciences industry.

The report noted that allocating proper resources for training individuals in aspects such as clinical trial coordination and execution, as well as standardising how clinical research is conducted and how study coordinators are trained, could drive better output and improve consistency.

Paraxel Academy offers world-class expert knowledge and practical experience to launch professionals' journeys in the field of clinical research.

The Academy is committed to setting global standards for education and training, and develops tailored, meaningful and effective education and training programs across Asia, Europe and the United States to meet the increasing demand for professionals and executives in the biopharmaceutical industry.

Paraxel International Corp. is a leading innovator of global biopharmaceutical services.

We simplify our clients' journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services.

Paraxel develops breakthrough innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, in more than 100 countries around the world. For more information, visit our website and follow us on LinkedIn and Twitter.